Free Trial
NASDAQ:TECH

Bio-Techne Q1 2027 Earnings Date & Estimates

Bio-Techne logo
$72.46 +0.01 (+0.01%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$72.20 -0.26 (-0.36%)
As of 10/9/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bio-Techne is scheduled to report Q1 2027 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 9:00 AM ET.

Upcoming Earnings Announcement

Quarter
Q1 2027
Announcement Date
Time
Before Market Opens
Conference Call
9:00 AM ET

What Analysts Expect from Bio-Techne in Q1 2027

Bio-Techne is expected to post earnings of $0.4433 per share on revenue of $292.61 million. In the same quarter a year earlier Bio-Techne reported $0.42 per share on revenue of $286.56 million. Bio-Techne last reported on August 12, 2026, posting $0.52 per share and beating the $0.5190 consensus estimate. Bio-Techne has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.4433
Expected Revenue
$292.61 million
Prior-Year EPS
$0.42
Prior-Year Revenue
$286.56 million
Expected EPS Growth
+5.5%
Expected Revenue Growth
+2.1%

Recent Track Record

Last Reported
Q4 2026
Last Quarter EPS
$0.52 (Beat by +$0.0010)
Last Quarter Revenue
$321.19 million
EPS Beat Rate
5 of last 8 quarters

Bio-Techne Q1 2027 Earnings FAQ

Bio-Techne (NASDAQ:TECH) is scheduled to report Q1 2027 earnings on Wednesday, November 4, 2026, before market opens.

Bio-Techne's Q1 2027 earnings conference call is scheduled for Wednesday, November 4, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Bio-Techne to post earnings of $0.4433 per share for Q1 2027.

The consensus revenue estimate for Bio-Techne is $292.61 million for Q1 2027.

Bio-Techne Earnings Headlines

Bio-Techne opens GMP small molecule facility in Bristol, UK
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
Contrasting Icon (NASDAQ:ICLR) & Bio-Techne (NASDAQ:TECH)
See More Bio-Techne Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bio-Techne? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bio-Techne and other key companies, straight to your email.

About Bio-Techne

Bio-Techne (NASDAQ:TECH)oration is a life sciences company that develops and supplies research, diagnostic and bioprocessing products for the biotechnology and pharmaceutical industries, academic institutions, clinical laboratories and other healthcare organizations. Its portfolio supports research in areas such as cancer, immunology, neuroscience, cell biology and precision medicine.

The company provides proteins, antibodies, immunoassays, reagents, gene and cell therapy materials, and analytical instruments. Its products are used to study biological processes, identify and validate disease biomarkers, develop and manufacture biopharmaceuticals, and support laboratory testing. Bio-Techne also offers technologies for spatial biology, single-cell analysis, protein characterization and tissue-based research through brands including R&D Systems, ProteinSimple, Advanced Cell Diagnostics, Tocris and Novus Biologicals.

Bio-Techne was formed in 2014 through the combination of R&D Systems and ProteinSimple, building on R&D Systems' history as a supplier of research reagents and proteins. The company serves customers internationally through operations, distribution networks and commercial activities across North America, Europe, Asia and other global markets.

View Bio-Techne Profile